# A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation and Inhalation Suspension Administered in Healthy Subjects and Multiple Doses in Patients With COPD.

> **NCT07116915** · PHASE1 · RECRUITING · sponsor: **Guangdong Hengrui Pharmaceutical Co., Ltd** · enrollment: 160 (estimated)

## Conditions studied

- COPD

## Interventions

- **DRUG:** HRS-9821 Powder for Inhalation/HRS-9821 inhalation suspension
- **DRUG:** HRS-9821 Powder for Inhalation placebo/HRS-9821 inhalation suspension placebo
- **DRUG:** Moxifloxacin Hydrochloride Tablets

## Key facts

- **NCT ID:** NCT07116915
- **Lead sponsor:** Guangdong Hengrui Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-11
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07116915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07116915, "A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation and Inhalation Suspension Administered in Healthy Subjects and Multiple Doses in Patients With COPD.". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT07116915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*